Hosted on MSN1mon
LEXX: IRB Approval Clears Way for GLP-1 Study #5
Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the ...
Nasdaq4y
Lexaria Bioscience Corp. Common Stock (LEXX) After-Hours
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
Nasdaq4y
Lexaria Bioscience Corp. Common Stock (LEXX) SEC Filings
There are no SEC filings that match your filter(s), please update your selections to return more records. Nasdaq provides company’s SEC filings, which are financial statements and reports filed ...
The Globe and Mail4mon
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has ...
The Globe and Mail3mon
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the ...